Nexus Surgical And Medicare Ltd vs Suven Life Sciences Ltd Stock Comparison

Home

Insights

Stock Comparison

Last Updated on: Oct 25, 2026

Key Highlights

The Latest Trading Price of Nexus Surgical and Medicare Ltd is ₹ 25.05 as of 23 Oct 15:30 . The P/E Ratio of Nexus Surgical and Medicare Ltd changed from 0 on March 2021 to 0 on March 2026 . This represents a CAGR of 0.0% over 6 yearsThe P/E Ratio of Uma Medicare Ltd changed from 0 on March 2021 to 0 on March 2026 . This represents a CAGR of 0.0% over 6 yearsThe P/E Ratio of Suven Life Sciences Ltd changed from 0 on March 2021 to 0 on March 2026 . This represents a CAGR of 0.0% over 6 years The Market Cap of Nexus Surgical and Medicare Ltd changed from ₹ 0 crore on March 2021 to ₹ 0 crore on March 2026 . This represents a CAGR of 0.0% over 6 yearsThe Market Cap of Uma Medicare Ltd changed from ₹ 0 crore on March 2021 to ₹ 0 crore on March 2026 . This represents a CAGR of 0.0% over 6 yearsThe Market Cap of Suven Life Sciences Ltd changed from ₹ 896.07 crore on March 2021 to ₹ 3503 crore on March 2026 . This represents a CAGR of 25.51% over 6 years The revenue of Nexus Surgical and Medicare Ltd for the Jun '26 is ₹ 0 crore as compare to the Mar '26 revenue of ₹ 0 crore. This represent the decline of 0% The revenue of Uma Medicare Ltd for the Jun '26 is ₹ 0 crore as compare to the Mar '26 revenue of ₹ 0 crore. This represent the decline of 0% The revenue of Suven Life Sciences Ltd for the Jun '26 is ₹ 11.09 crore as compare to the Mar '26 revenue of ₹ 8.3 crore. This represent the growth of 33.61% The ebitda of Nexus Surgical and Medicare Ltd for the Jun '26 is ₹ 0 crore as compare to the Mar '26 ebitda of ₹ 0 crore. This represent the decline of 0% The ebitda of Uma Medicare Ltd for the Jun '26 is ₹ 0 crore as compare to the Mar '26 ebitda of ₹ 0 crore. This represent the decline of 0% The ebitda of Suven Life Sciences Ltd for the Jun '26 is ₹ -124 crore as compare to the Mar '26 ebitda of ₹ -43.86 crore. This represent the growth of 184.95% The net profit of Nexus Surgical and Medicare Ltd changed from ₹ 0 crore to ₹ 0 crore over 9 quarters. This represents a CAGR of 0.0% The net profit of Uma Medicare Ltd changed from ₹ 0 crore to ₹ 0 crore over 9 quarters. This represents a CAGR of 0.0% The net profit of Suven Life Sciences Ltd changed from ₹ -28.04 crore to ₹ -127 crore over 9 quarters. This represents a CAGR of 96.11% The Dividend Payout of Nexus Surgical and Medicare Ltd changed from 0 % on March 2021 to 0 % on March 2026 . This represents a CAGR of 0.0% over 6 yearsThe Dividend Payout of Uma Medicare Ltd changed from 0 % on March 2021 to 0 % on March 2026 . This represents a CAGR of 0.0% over 6 yearsThe Dividend Payout of Suven Life Sciences Ltd changed from 0 % on March 2021 to 0 % on March 2026 . This represents a CAGR of 0.0% over 6 years .

About Nexus Surgical and Medicare Ltd

Nexus Surgical & Medicare Limited was formerly incorporated as Nexus Commodities and Technologies Limited in 1992.
The Company came out with a public issue in Aug.'96 to part-finance the project.
Later, the name of the Company was changed to Nexus Surgical & Medicare Limited in August 2020.
The Company is engaged into trading of medical essentials.
Prior to this, it was promoted by a group of technocrats to manufacture and market premium consumer durables and domestic appliances. The Company is a wholesale dealer dealing in various sizes of disposal syringe (with and without needle) and pouches of various size used for storage of sterilized equipment and materials.

About Suven Life Sciences Ltd

Suven Life Sciences Limited, formerly known as Suven Pharmaceuticals Limited was incorporated in March, 1989.
The Company changed its name from Suven Pharmaceuticals Limited to Suven Life Sciences Limited in September, 2003.
Promoted by Venkateswarlu Jasti, Company began its operations in 1989 as specialty chemicals provider. The Company is a clinical-stage biopharmaceutical company focused on the acquisition, development and commercialization of novel therapeutics for the treatment of neurodegenerative disorders.
Suven has a wholly owned subsidiary, Suven Neurosciences, Inc., USA, focused on clinical development activities of Suven molecules from phase 2, Proof-of-Concept (POC) studies. The Company is in the business of Contract Research And Manufacturing Services (CRAMS), catering to the needs of global life science industry and fine chemical majors.

FAQs for the comparison of Nexus Surgical and Medicare Ltd and null

Which company has a larger market capitalization, Nexus Surgical and Medicare Ltd or Uma Medicare Ltd?

Market cap of Nexus Surgical and Medicare Ltd is 13 Cr while Market cap of Uma Medicare Ltd is 0 Cr

What are the key factors driving the stock performance of Nexus Surgical and Medicare Ltd and Uma Medicare Ltd?

The stock performance of Nexus Surgical and Medicare Ltd and Uma Medicare Ltd is primarily driven by its robust global client base, consistent revenue growth, strong operational efficiency, strategic investments in digital transformation, client acquisition, and the overall health of the industry. Both companies' performances are also influenced by macroeconomic conditions, currency fluctuations, and industry-specific trends.

What are the recent stock price for Nexus Surgical and Medicare Ltd and Uma Medicare Ltd?

As of October 25, 2026, the Nexus Surgical and Medicare Ltd stock price is INR ₹25.05. On the other hand, Uma Medicare Ltd stock price is INR ₹0.0.

How do dividend payouts of Nexus Surgical and Medicare Ltd and Uma Medicare Ltd compare?

To compare the dividend payouts of Nexus Surgical and Medicare Ltd and Uma Medicare Ltd, examine their dividend payout ratio, which indicates how much the companies pay out relative to their share price and earnings. Moreover, consider the consistency and growth of their dividends to gauge their commitment towards returning value to the respective shareholders.

Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.